BeOne Medicines remains a strong buy despite a modest 2026 guidance miss, with a $410/share 12-month price target. Brukinsa's 49% YoY growth to $3.93B in 2025 and best-in-class CLL data underpin ONC’s ...

The hottest sector of 2026 by far has been energy. Through Feb. 20, the Vanguard Energy ETF (VDE 0.07%) is up 23%, far outpacing the S&P 500's scant 1% return. The good times might not be over yet.

Management described 2026 as a transition year, prioritizing execution, near-term launches, and the advancement of late-stage pipeline assets. Smiley stated, "we're looking for good commercial ...

Alphabet is the best-performing Magnificent Seven stock over the past year and has multiple catalysts that could extend its lead. It has a comfortable lead in the search engine market and is gaining ...

Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line. Focused investment in Idorsia’s pipeline of first-in ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

A manufacturing problem in Abbott glucose sensors for diabetes patients has been tied to at least seven deaths and hundreds ...

Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.

U.S. drone stock investors are looking at profitable industry forecasts and outperformance these days. For starters, the global drone market was valued at $83.8 billion in 2025 and is expected to ...